Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled trials.
Claudio MontaltoRenato Francesco Maria ScaliseSergio LeonardiAntonio MicariJacopo A OregliaPascal VranckxDavide CapodannoJurriën Ten BergRenato Deláscio LopesMarco ValgimigliPublished in: European heart journal. Cardiovascular pharmacotherapy (2022)
In patients undergoing PCI with concomitant OAC indication, an abbreviated DAPT regimen reduced MCRB and major bleeding without increasing MACE or other ischemic events. Peri-procedural DAPT and P2Y12 inhibitor monotherapy after DAPT withdrawal appear to be the best strategies to optimize the bleeding and ischemic risk tradeoff.
Keyphrases
- antiplatelet therapy
- percutaneous coronary intervention
- atrial fibrillation
- acute coronary syndrome
- st segment elevation myocardial infarction
- patients undergoing
- st elevation myocardial infarction
- acute myocardial infarction
- coronary artery disease
- coronary artery bypass grafting
- ischemia reperfusion injury
- coronary artery bypass
- cerebral ischemia
- open label
- heart failure
- combination therapy
- blood brain barrier
- left ventricular